Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer

Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix™ is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.

[1]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.

[2]  R. Schlegel,et al.  HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. , 1992, Virology.

[3]  C. Wheeler,et al.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.

[4]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[5]  T. Sasagawa,et al.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6and Type 16 in fission yeast Schizosaccharomyces pombe , 1995 .

[6]  P. De Grandi,et al.  Improved Efficiency of a Salmonella-Based Vaccine against Human Papillomavirus Type 16 Virus-Like Particles Achieved by Using a Codon-Optimized Version of L1 , 2004, Journal of Virology.

[7]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[8]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[9]  R. Garcea,et al.  Immunization with a Pentameric L1 Fusion Protein Protects against Papillomavirus Infection , 2001, Journal of Virology.

[10]  W. White,et al.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. , 2001, The Journal of infectious diseases.

[11]  R. Roden,et al.  Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2 , 2007, Journal of Virology.

[12]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[13]  C. Wheeler,et al.  Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .

[14]  M. Li,et al.  Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly , 1997, Journal of virology.

[15]  R. Schlegel,et al.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Lowy,et al.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. , 1996, Virology.

[17]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[18]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[19]  N. Christensen,et al.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus , 1996, Journal of virology.

[20]  D. Lowy,et al.  Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. , 2005, Vaccine.

[21]  H. Schild,et al.  Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1 , 2005, The Journal of Immunology.

[22]  N. Christensen,et al.  Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein , 2002, Journal of Virology.

[23]  E. de Villiers.  Heterogeneity of the human papillomavirus group , 1989, Journal of virology.

[24]  R. Roden,et al.  How will HPV vaccines affect cervical cancer? , 2006, Nature Reviews Cancer.

[25]  S. Harrison,et al.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. , 2000, Molecular cell.

[26]  C. Berkower,et al.  Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. , 2006, Vaccine.

[27]  W. White,et al.  Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies , 1998, Journal of Virology.

[28]  M. Sapp,et al.  Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. , 2001, Virology.

[29]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[30]  A. Roberts,et al.  Intranasal Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing Cottontail Rabbit Papillomavirus L1 Protein Provides Complete Protection against Papillomavirus-Induced Disease , 2002, Journal of Virology.

[31]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[32]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Curtiss,et al.  Immunogenicity against Human Papillomavirus Type 16 Virus-Like Particles Is Strongly Enhanced by the PhoPc Phenotype in Salmonella enterica Serovar Typhimurium , 2004, Infection and Immunity.

[34]  R. Roden,et al.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice , 1997, Infection and immunity.

[35]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[36]  D. Lowy,et al.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.

[37]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[38]  M. Lehtinen,et al.  Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[39]  D. Lowy,et al.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.

[40]  R. Reichman,et al.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. , 1994, The Journal of general virology.

[41]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[42]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[43]  M. Schiff,et al.  Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. , 2004, Vaccine.

[44]  J. Dillner,et al.  Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. , 1995, Virology.

[45]  R. Roden,et al.  Opportunities to improve the prevention and treatment of cervical cancer. , 2007, Current molecular medicine.

[46]  C. Wheeler,et al.  Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine , 2007 .

[47]  A. Giuliano,et al.  A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. , 2004, Vaccine.

[48]  Y. L. Lin,et al.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product , 1993, Journal of virology.

[49]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[50]  X. Castellsagué,et al.  Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women , 2006, Pediatrics.

[51]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.